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ABSTRACT
Evaluation of clinical effectiveness of medical devices differs in some aspects from the evaluation of pharmaceuticals. One
of the main challenges identiﬁed is lack of robust evidence and a will to make use of experimental and observational studies
(OSs) in quantitative evidence synthesis accounting for internal and external biases. Using a case study of total hip replace-
ment to compare the risk of revision of cemented and uncemented implant ﬁxation modalities, we pooled treatment effect
estimates from OS and RCTs, and simpliﬁed existing methods for bias-adjusted evidence synthesis to enhance practical
application.
We performed an elicitation exercise using methodological and clinical experts to determine the strength of beliefs about
the magnitude of internal and external bias affecting estimates of treatment effect. We incorporated the bias-adjusted treat-
ment effects into a generalized evidence synthesis, calculating both frequentist and Bayesian statistical models. We esti-
mated relative risks as summary effect estimates with 95% conﬁdence/credibility intervals to capture uncertainty.
When we compared alternative approaches to synthesizing evidence, we found that the pooled effect size strongly
depended on the inclusion of observational data as well as on the use bias-adjusted estimates. We demonstrated the feasi-
bility of using observational studies in meta-analyses to complement RCTs and incorporate evidence from a wider spectrum
of clinically relevant studies and healthcare settings. To ensure internal validity, OS data require sufﬁcient correction for
confounding and selection bias, either through study design and primary analysis, or by applying post-hoc bias adjustments
to the results. © 2017 The Authors. Health Economics published by John Wiley & Sons, Ltd.
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1. INTRODUCTION
In many countries, comparative effectiveness research (CER) is well established as part of health technology
assessment (HTA) of pharmaceutical therapies (Panteli, 2016). (Although, there is no consensus on how to op-
timally implement CER for medical devices (MDs), developing and promoting the use of methodological guid-
ance for the evaluation of MDs within an HTA framework is a goal for the European network for Health
Technology Assessment (EUnetHTA) (www.eunethta.eu) in Joint Action 2 (2012–2015) and 3 (2016–2019)
(Schnell-Inderst et al. 2015). A primary challenge, identiﬁed through conducting HTAs of MDs, is the lack
of robust evidence on clinical effectiveness and cost-effectiveness (Iglesias, 2015).
MDs typically show rapid and incremental development with product life cycles shorter than three years
(Siebert et al., 2002, Schulenburg et al., 2009), which results in frequent technology updates that often demon-
strate only minor modiﬁcations and market access of similar competing products. The need for new randomized
clinical trials (RCTs) to demonstrate the incremental effectiveness of marginal modiﬁcations of MDs may be im-
practicable, limited by insufﬁcient sample size, limited follow-up time and costs (Konstam et al., 2003). RCT de-
signs that can account for the incremental development process, and the additional challenges of MDs, such as
patient and clinician preferences, the lack of double-blinding and technology changes over time have been pro-
posed (Bernard et al. 2014, Royal Netherlands Academy of Arts and Sciences 2014). Including empirical data on
the clinical effectiveness from observational studies (OS) can complement evidence from RCTs. Device- and
disease-speciﬁc registries have been established to provide long-term data on the effectiveness and safety of
MDs in routine clinical practice. These registry data are being used to help guide clinical practice and medical
decision making, and are especially relevant in the case of MDs where effectiveness often relies on user proﬁ-
ciency (i.e. a ‘learning curve’) and contextual factors, including the clinical setting in which theMD is being used.
There are some indications of a will to use evidence from RCT and observational studies complementarily.
For example, HTA agencies, such as the National Institute for Health and Care Excellence (NICE) in United
Kingdom, often require identiﬁcation of all of the relevant sources of evidence, and do not restrict evidence
synthesis to RCTs (NICE 2013). As OSs are prone to selection bias and confounding, the appropriateness of
combining experimental and observational evidence quantitatively is the subject of debate (Verde and Ohmann,
2014). The Cochrane Collaboration recommends considering the two types of evidence separately and not pool
the different study designs (Higgins and Green, 2011) into a single summary effect estimate. Statistical methods
for generalized evidence synthesis approaches perform bias adjustments of observational and randomized
evidence are increasingly being published. A recently published review identiﬁed 20 unique statistical
approaches (in addition to the traditional ﬁxed- or random-effects meta-analytic methods) to combine random-
ized and non-randomized studies in clinical research (Verde and Ohmann 2014). In 15 of these approaches,
there were alternative bias-adjustment approaches, 12 of which used Bayesian methods. Bias correction
methods propose either down-weighting studies with a high risk of bias or modelling study-speciﬁc biases
based on individual study characteristics. Observed treatment effects are typically adjusted at the individual
study level prior to synthesizing the evidence (Welton and Ades, 2009, Welton et al. 2012). One particular
approach, described by Turner et al. (2009), allows, at least theoretically, for a complete bias correction by
adjusting the observed treatment effects for internal and external biases at the individual study level using
expert elicitation, followed by synthesizing across multiple studies. This approach follows standard HTA
methods where risk of bias assessments is performed at the individual study level. Despite the advantages of
this approach, to our knowledge, it has been rarely implemented in practice (Verde and Ohmann 2014).
In this study, we aim to: (i) illustrate the use of current statistical methods to combine treatment effect esti-
mates from observational studies and RCTs using an illustrative application of total hip replacement (THR)
prostheses as a case-study for assessing the clinical effectiveness of MDs, and (ii) simplify existing methods
for bias-adjusted evidence synthesis to enhance practical application by HTA practitioners.
As the main objective of this analysis is to illustrate the application of statistical methods, readers are
cautioned that our ﬁndings should not be considered as deﬁnitive evidence to support any claim on the clinical
effectiveness associated with THR prostheses which we have used as our case study.
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2. METHODS
2.1. Rationale for the choice of the case example
THR illustrates the life cycle of medical device technology and clinical evidence production/development well.
A total hip construct consists of a femoral component that articulates with an acetabular component (see
Appendix Table A1 for a classiﬁcation of prostheses). THR is an MD with a relatively well-supported clinical
effectiveness evidence base that includes RCTs as well as data from numerous large national registries, and is
well-suited to use as an illustrative application of generalized evidence synthesis approaches that combine RCT
and OSs in a meta-analysis (Clarke et al. 2013).
2.2. Methodological framework to synthesize RCT and observational evidence
We followed the methodology proposed by Turner et al. (2009), to conduct a generalized evidence synthesis to
combine observational and RCT evidence on the clinical effectiveness of different ﬁxation methods of THR.
The approach used by Turner et al. was considered by members of the MedtecHTA consortium as a method-
ological framework that: (i) provided a comprehensive approach for bias adjustment in the context of evidence
synthesis; (ii) while resource intensive outlined a rationale that was fairly intuitive and easier to follow than that
of other statistical approaches for bias adjustment; (iii) explicitly acknowledged the role of expert judgement
for bias elicitation in medical device evaluation; and (iv) promoted the use of standard (i.e. simpler) methods
for evidence synthesis (i.e. meta-analysis) than other statistical approaches for bias-adjusted evidence synthesis.
Similar to Turner and colleagues, we performed our analysis using the following ﬁve steps (for details see
original publication (Turner et al., 2009)): (i) framed the clinical target question; (ii) identiﬁed the relevant ev-
idence base; (iii) extracted data, assessed bias and transformed reported treatment effect estimates; (iv) elicited
expert opinion to determine bias-adjusted treatment effects; and (v) performed quantitative synthesis of RCT
and observational data, meta-regression and sensitivity analyses.
2.3. Target question
Our case example target question asked, ‘Which ﬁxation method—cemented or uncemented—is more effective
in terms of revision rate for adult patients with end stage hip arthritis undergoing THR?’We speciﬁed this ques-
tion according to the following PICOS framework:
• Population: Adult population (>18 years) with end stage hip arthritis for whom non-surgical manage-
ment has failed;
• Intervention: Cemented THR with a polyethylene-metal articulation;
• Comparator: Uncemented THR with a polyethylene-metal articulation;
• Outcomes: Revision risk at ≥5 years follow-up.
• Target setting: THR procedure applicable in a United Kingdom (UK) district general hospital.
2.4. Evidence base
We identiﬁed the evidence base for this study using four previously published systematic reviews of THRs un-
dertaken by the HTA Programme in UK (Clarke et al., 2013, Faulkner et al., 1998, Fitzpatrick et al.,1998, Vale
et al., 2002) and four additional systematic reviews cited in reports (Tsertsvadze et al., 2014, Clement
et al.,2012, Pakvis et al., 2011, Voigt and Mosier, 2012).
We focused on a subset of THR evidence, that is, all RCTs and OSs (i.e. cohort studies, case-control studies
or registries) that directly compared the cemented and uncemented ﬁxation methods for hip implants. Where
multiple publications from the same population/study were identiﬁed, we selected the most recent publication.
We excluded reports where core data for the analyses were not available or where no revisions occurred during
follow-up. Duplicate publications and national registry reports from outside the European Union (EU) were ex-
cluded because they may not be applicable within the UK setting; however, we included cohort studies con-
ducted outside the EU, if their setting was deemed potentially applicable to the UK setting.
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2.5. Outcome measure
Because our initial review identiﬁed few studies that reported hip implant revisions in terms of time-to-event, we
used the more commonly reported metric of the proportion of patients who received a revision during follow-up.
For this outcome, we calculated (crude) relative risks (RR) and 95% conﬁdence intervals (95%CI) for each study
comparing the cemented versus uncemented ﬁxation approach. We selected RR rather than odds ratios (OR) as
our preferred metric as they are easier to understand by clinical experts (Froud et al. 2012). We also extracted
RRs adjusted for baseline covariates (i.e. confounder-adjusted RR) from a subset of studies, if reported.
2.6. Data extraction, bias assessment and transformation of reported treatment effect estimates
For each included study, we extracted study design (e.g. RCT, cohort and registry), duration of follow-up
(in years), population characteristics (e.g. mean age, proportion of women) and the proportion of revisions in
each treatment arm and/or the confounder-adjusted RR and 95%CI. For each study, internal biases were assessed
using the Cochrane risk of bias tool (Sterne et al. 2014). External biases were assessed using the framework pro-
posed by Dekkers et al. (2010) and Rothwell (2010). Two authors (OC, MA) extracted data, while bias assess-
ment was initially conducted by a single author (OC), and conﬁrmed by a second author (RST).
2.7. Expert elicitation to determine bias-adjusted treatment effects
To improve the feasibility and practical implementation of eliciting bias-adjustment weights suggested by Turner
et al., we made four main adaptions that included: (i) eliciting bias-adjusted treatment effects directly rather than
for biases per se; (ii) eliciting overall bias at the level of each study rather than for each individual bias separately;
(iii) using a modiﬁed elicitation tool; and (iv) incorporating a qualitative tool to aid experts when undertaking their
bias assessment. The bias elicitation process is summarized in Figure 1. A trained facilitator (OC/RST) introduced the
elicitation tasks and invited experts to complete the questions individually. Experts were provided with a qualitative
tool to assist them completing the elicitation task. During two separate and consecutive meetings, internal biases
(Appendix Table A2) were elicited from methodological experts and external biases (Appendix Table A3) from cli-
nicians. The Turner et al. bias-adjustment method recognizes that the impact of biases on treatment effects may differ
across different types of biases and suggests individually eliciting bias adjusting weights for each bias type and study.
Figure 1. Summary of elicitation exercise methodology
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Preliminary consultation with experts during a pilot session indicated that they may struggle to elicit these unobserv-
able quantities; therefore, we elected to elicit internal and external bias weights aggregately, for each study.
Detailed information on the elicitation exercises are provided in our full report for MedTecHTA projectWP3 to
the EU, and are available upon request. Brieﬂy, in a ﬁrst meeting, the impact of internal biases on the THR revision
RRs was elicited by methodologists, while a follow-up meeting with orthopaedic surgeons elicited the impact of
external biases. For each study, participants were ﬁrst asked to complete a qualitative tool that asked them to qual-
itatively assess the likely importance or direction of each bias attribute (e.g. selection bias, performance bias)
(Appendix Figure A1). At the ﬁrst meeting, methodologists were presented with the calculated crude THR RRs
and 95% CIs. Methodologists were asked to provide what they considered would be an unbiased treatment effect
by indicating the RRs and 95%CI estimates on a grid provided in the elicitation tool for each study after consid-
ering the speciﬁed internal biases identiﬁed for each study (see Appendix Figure A2). At the second meeting for
external bias elicitation, the study-speciﬁc RR and 95% CIs presented to each surgeon were the ‘typical’ value es-
timated from the ﬁrst methodologists’ meeting. We calculated the ‘typical’ value by taking the median of mean
effect, and the upper and lower CIs of these estimates, for the bias-adjusted RR (95% CI) across all assessors of
each study (Appendix Figure A3). This was done so that the starting point for assessment of external bias by sur-
geons was already conditioned by the internal bias adjustment performed by the methodologists, subsequently
allowing an ex post calculation of the magnitude of the internal and external biases. Surgeons were asked to pro-
vide their estimate of the unbiased treatment effect assuming all external biases had been removed.
The two elicitationmeetingswere held betweenMay and June 2015, each lasting 2 to 3 h. Ninemethodologists and
eleven orthopedic surgeons attended each workshop. Each expert received ﬁve to seven studies to assess, distributed
randomly. All nine methodologists were drawn from the Institute of Health Research, University of Exeter Medical
School in England and included statisticians, epidemiologists, trialists and health service researchers. The elicitation
of external biases was undertaken by eleven orthopedic surgeons, practicing in Bristol in the South West of England.
To accurately quantify a participant’s adjusted RR and 95% CI, the quantitative bias-assessment graph for
all studies and all participants was digitized using Plot Digitizer 2.6.6© Dice 2014 software. These estimates
for the fully bias-adjusted RR (95% CI) were then pooled across participants by taking the median of mean ef-
fect, and upper and lower CIs, to obtain a bias-adjusted treatment-effect for a ‘typical’ assessor. Finally, the
log(RR) and standard errors were derived for the observed, methodologist ‘typical’ assessor and surgeon ‘typ-
ical’ assessor treatment effect for each study, to correct for potentially asymmetrical CIs provided by experts.
2.8. Synthesis of randomized and non-randomized data
2.8.1. Main steps of synthesis. We used different stepwise synthesis models (see below) to pool the reported
and bias-adjusted RR of the revision rate that included: (i) RCTs only; (ii) RCTs and registries; and (iii) from
all types of study designs (i.e. RCTs, registries and cohorts). In a hierarchical model distinguishing already
between study types, all studies were included in a single step. We pre-speciﬁed subgroup analyses for
variables from the literature that are recognized as inﬂuencing treatment effect (i.e. patient age, gender and
mobility) and additional variables of interest (i.e. duration of follow-up and study type). Univariate and
multivariate meta-regression analyses were conducted for these variables to investigate effect modiﬁcation.
2.8.2. Analyses and statistical models of meta-analyses. We pooled studies using standard frequentist ﬁxed ef-
fect model (FEM) and random effects model (REM) meta-analysis in STATA 14.1 using commands ‘metan’ and
‘admetan’ (Stata Corp LP, College Station, TX). Additionally, we undertook two different Bayesian approaches
to meta-analysis: (i) Bayesian random effects meta-analysis (BREM) using conjugate, non-informative priors
(normal and uniform (0;10) distributions for mean and variance, respectively) and posterior RRs; their standard
deviations (SD) were empirically estimated and approximated using Monte Carlo simulation with 100 000 rep-
etitions; (ii). Bayesian hierarchical meta-analysis (BHM) that accounts for the variability between different study
types in addition to variability within and between studies (Welton et al., 2012). All Bayesian analyses were per-
formed inWinBUGS software version 1.4.3, 2007 (Lunn et al., 2000) adapting the codes byWelton et al. (2012).
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For subgroup analyses, missing values were imputed using the mean value from all studies in each arm. Con-
tinuous variables were divided into two subgroups with the median as cut-point. Frequentist meta-regression
was performed with the command ‘metareg’ in STATA 14.1 and Bayesian meta-regression withWinBUGS. Be-
cause of the limited number of studies and the potential of overﬁtting, we used forward variable selection from
the pre-speciﬁed variables. The degree of statistical heterogeneity was assessed by calculating I-square (I2) and
tau-square (τ2). We calculated the conﬁdence or credibility interval limits ratio (CILR) between the upper and the
lower bound as a measure of the relative width of the conﬁdence or credibility intervals (CrIs), respectively.
We performed sensitivity analyses by varying the assumptions for priors in BREM and BHM. We used a
t-distribution for the mean and three different weakly informative priors for the variance (i.e. Gamma,
Inverse-Gamma, and Half-Cauchy distributions), as suggested by Gelman (2006).
3. RESULTS
3.1. Study selection
We included a total of 15 studies into our evidence synthesis: seven RCTs (Angadi et al., 2012; Bjorgul et al.,
2010; Corten et al., 2011; Kim et al., 2011; McCombe and Williams; 2004, Reigstad et al., 1993; Wykman
et al. 1991), ﬁve cohort studies (Clohisy and Harris, 2001; Kim et al., 2003; Kruckhans and Dustmann,
2004; Pospula et al., 2008; Hartoﬁlakidis et al., 2009) and three reports from national arthroplasty registries
(Hailer et al., 2010; Makela et al., 2011; Pennington et al., 2013). The study selection process is illustrated in
Figure 2, and a full citation listing of the included studies is provided in the Supplementary Web Appendix.
Figure 2. Study selection process
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3.2. Study characteristics
Studies were published between 1993 and 2013 with a follow-up between 5 and 20 years (Table I). The mean
age of study participants varied between 42.5 and 70.2 years, and the proportion of females included in each
study ranged from 20 to 80%. Comparable data on the degree of mobility were not available for both study
arms. The registry-based studies reported RRs adjusted for different baseline variables, while RCTs and cohort
studies did not control for confounding factors.
3.3. Bias elicitation exercise
In general, the ﬁrst meeting with methodologists revealed that for each study they were either uncertain
about the impact of internal bias on the revision rates or felt the internal bias had no impact on the outcome
(Table II and Appendix Table A4). Their judgment did not appear to be inﬂuenced by whether the study
was an RCT or an OS. The methodologists appeared to generally agree on the effect of the biases; how-
ever, there were exceptions (e.g. qualitative assessment of the impact of selection bias in Kruckhans
et al. (2004)).
Table I. Study and patient characteristics for the 15 included studies
Study
Study
type
N of revisions/
total cemented
N of revisions/
total
uncemented
Relative risks
computed/reported
(95% CI)
Overall
mean age
(years)
Overall
proportion of
women
Follow-
up (years)
Wykman
(1991)
RCT 8/90 14/94 0.60 (0.26–1.35) 66.1 0.5 5
Reigstad
(1993)
RCT 0/60 2/60 0.20 (0.01–4.08) 64.5 0.7 5
McCombe
(2004)
RCT 0/84 4/78 0.10 (0.01–1.89) 67.4 n.r. 8
Bjorgul
(2010)
RCT 9/120 4/120 2.25 (0.71–7.11) 65.5 0.7 10
Corten (2011) RCT 48/124 31/126 1.57 (1.08–2.29) 64.0 0.5 7
Kim (2011) RCT 17/114 22/114 0.77 (0.43–1.38) 45.1 0.2 20
Angadi
(2012)
RCT 17/183 11/104 0.88 (0.43–1.80) 70.2 0.6 10
Hailer (2010) Registry 9689/161460a 1343/8953a 0.67 (0.62–0.71)b n.r. 0.6 10
Makela
(2011)
Registry 197/1535a 60/579a 0.85 (0.62–1.16)b 65.0 0.8 15
Pennington
(2013)
Registry 216/16882a 420/18845a 0.60 (0.55–0.66)b 70.2 0.4 5
Clohisy
(2001)
Cohort 1/45 2/45 0.50 (0.05–5.32) 61.5 0.5 10
Kim (2003) Cohort 7/42 8/45 0.94 (0.37–2.36) 46.8 0.4 10
Kruckhans
(2004)
Cohort 10/200 26/200 0.38 (0.19–0.78) 63.7 0.5 5
Pospula
(2008)
Cohort 2/87 1/96 2.21 (0.20–23.9) 50.2 0.6 5
Hartoﬁlakidis
(2009)
Cohort 14/50 18/51 0.79 (0.40–1.42) 42.5 0.6 10
n.r., not reported; CI, conﬁdence interval; RCT, randomized controlled trial; RR, relative risk.
aNumbers of revisions were taken from reported numbers in the study publications (10-year-survival, total number of revisions and 5-year
revision rates in Hailer, Makela and Pennington, respectively).
bReported RR (95% CI) adjusted for patient level covariates (Hailer: adjusted for sex, age and primary diagnosis; Makela: adjusted
for age and sex; Pennigton: adjusted for age, sex, BMI, ASA grade, surgeon grade, hospital type, Charlson score and date of
surgery).
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In contrast, the orthopedic surgeons provided stronger opinions about the effects external biases may have
on the results of the studies (Table III and Appendix Table A5). According to the surgeons, RCTs were less
likely to result in external biases; although, one of the dimensions of external validity (i.e. How was the out-
come measured? Who measured the outcome? Adequacy of the length of follow-up?) had the highest degree
of variation in judgment across participants’ replies.
In general, the bias-adjusted mean treatment effects provided by experts resulted in less effective estimates
(Table IV). However, there was a single case where adjusting for bias changed from favoring uncemented im-
plants to favoring cemented implants. The standard error of treatment effect estimate generally increased after
bias adjustment indicating increased uncertainty as a result of the bias-adjustment process, although there were
some exceptions.
Table II. Qualitative bias-assessment—proportion of methodologists reporting likely impact of internal biases for each
study
Study Study type
Not causing any bias/not
likely to favor either implant
Likely to favor
cemented implant
Likely to favor
uncemented implant Do not know
Wykman (1991) RCT 0.13 0.08 0.00 0.79
Reigstad (1993) RCT 0.04 0.21 0.04 0.71
McCombe (2004) RCT 0.17 0.17 0.04 0.63
Bjorgul (2010) RCT 0.21 0.08 0.21 0.50
Corten (2011) RCT 0.58 0.04 0.04 0.33
Kim (2011) RCT 0.25 0.13 0.00 0.63
Angadi (2012) RCT 0.25 0.04 0.21 0.50
Hailer (2010) Registry 0.25 0.00 0.04 0.71
Makela (2011) Registry 0.42 0.08 0.04 0.46
Pennington (2013) Registry 0.17 0.04 0.17 0.63
Clohisy (2001) Cohort 0.52 0.06 0.04 0.39
Kim (2003) Cohort 0.04 0.13 0.13 0.71
Kruckhans (2004) Cohort 0.17 0.08 0.08 0.67
Pospula (2008) Cohort 0.17 0.08 0.25 0.50
Hartoﬁlakidis (2009) Cohort 0.29 0.00 0.29 0.42
RCT, randomized controlled trial.
Table III. Qualitative bias-assessment—proportion of orthopaedic surgeons reporting likely impact of external biases for
each study
Study Study type
Not causing any bias/not
likely to favor either implant
Likely to favor
cemented implant
Likely to favor
uncemented implant Do not know
Wykman (1991) RCT 0.40 0.25 0.25 0.10
Reigstad (1993) RCT 0.65 0.20 0.05 0.10
McCombe (2004) RCT 0.75 0.25 0.00 0.00
Bjorgul (2010) RCT 0.65 0.10 0.25 0.00
Corten (2011) RCT 0.65 0.00 0.35 0.00
Kim (2011) RCT 0.70 0.05 0.20 0.05
Angadi (2012) RCT 0.65 0.10 0.25 0.00
Hailer (2010) Registry 0.45 0.35 0.15 0.05
Makela (2011) Registry 0.55 0.20 0.15 0.10
Pennington (2013) Registry 0.50 0.25 0.25 0.00
Clohisy (2001) Cohort 0.40 0.02 0.49 0.09
Kim (2003) Cohort 0.45 0.10 0.40 0.05
Kruckhans (2004) Cohort 0.35 0.40 0.20 0.05
Pospula (2008) Cohort 0.35 0.05 0.40 0.20
Hartoﬁlakidis (2009) Cohort 0.50 0.15 0.30 0.05
RCT, randomized controlled trial.
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3.4. Evidence synthesis
All bias-unadjusted meta-analytic results from the same study design were included in a stepwise fashion in
FEM, REM and BREM starting with RCTs, which were considered to have the highest internal validity, and
were repeated for bias-adjusted RRs (Table V). As BHM inherently accounts for the variance of different study
designs in the statistical model, a stepwise inclusion is not possible.
Table IV. Elicited bias-adjusted treatment effects by study
Study Study type Assessor Elic RR Elic LB 95% CI Elic UB 95%CI
Wykman (1991) RCT Typical assessora 0.5 0.1 1.2
Typical assessor methodb 0.64 0.32 1.4
Observedc 0.6 0.26 1.35
Reigstad (1993) RCT Typical assessor 0.6 0.04 9.69
Typical assessor method 0.5 0.02 7.89
Observed 0.2 0.01 4.08
McCombe (2004) RCT Typical assessor 0.33 0.1 3.75
Typical assessor method 0.27 0.02 5.61
Observed 0.1 0.01 1.89
Bjorgul (2010) RCT Typical assessor 1.5 0.7 3.5
Typical assessor method 1.61 0.52 4.8
Observed 2.25 0.71 7.11
Corten (2011) RCT Typical assessor 1.53 1.08 1.95
Typical assessor method 1.57 1.08 2.29
Observed 1.57 1.08 2.29
Kim (2011) RCT Typical assessor 0.71 0.42 1.58
Typical assessor method 0.79 0.44 1.64
Observed 0.77 0.43 1.38
Angadi (2012) RCT Typical assessor 0.8 0.37 1.77
Typical assessor method 0.83 0.45 1.65
Observed 0.88 0.43 1.80
Hailer (2010) Registry Typical assessor 0.82 0.72 0.96
Typical assessor method 0.68 0.57 0.76
Observed 0.67 0.62 0.71
Makela (2011) Registry Typical assessor 0.87 0.63 1.27
Typical assessor method 0.85 0.63 1.12
Observed 0.85 0.62 1.16
Pennington (2013) Registry Typical assessor 0.67 0.55 0.9
Typical assessor method 0.66 0.48 0.77
Observed 0.6 0.55 0.66
Clohisy (2001) Cohort Typical assessor 0.55 0.05 7.6
Typical assessor method 0.69 0.06 7.2
Observed 0.5 0.05 5.32
Kim (2003) Cohort Typical assessor 0.63 0.2 3.52
Typical assessor method 0.86 0.35 2.58
Observed 0.94 0.37 2.36
Kruckhans (2004) Cohort Typical assessor 0.45 0.15 1.45
Typical assessor method 0.38 0.25 0.6
Observed 0.38 0.19 0.78
Pospula (2008) Cohort Typical assessor 0.78 0.08 8
Typical assessor method 1 0.15 15.76
Observed 2.21 0.2 23.91
Hartoﬁlakidis (2009) Cohort Typical assessor 0.8 0.43 1.38
Typical assessor method 0.67 0.35 1.24
Observed 0.79 0.44 1.42
Elic RR, elicited relative risk; Elic LB 95% CI, elicited lower bound of the 95% conﬁdence interval; Elic UB 95%, elicited upper bound of
the 95% conﬁdence interval.
aAccounts for internal and external bias elicitation.
bAccounts for internal bias elicitation alone.
cEmpirically observed results from the published study.
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3.4.1. Bias-unadjusted effect estimates of stepwise inclusion by study type. When we only considered
unadjusted evidence from RCTs in the FEM, REM (Figure 3) and BREM meta-analyses, the pooled effect
estimates did not show any favorable statistically signiﬁcant effect for either treatment modality. After
adding the three registry studies with their larger sample sizes, the level of statistical uncertainty decreased
and we identiﬁed a statistically signiﬁcant effect for one treatment approach for the FEM and REM
analyses, but not in the BREM analysis. After including registry-based studies, the CILR reduced for
all three models. Adding the ﬁve cohort studies with comparably small sample sizes only slightly changed
the effect estimate and CI/CrIs. For BHM, the point estimate was similar to the REM and BREM
analyses; however, the CrIs were wider and did not show a differing treatment effect (i.e. still included a
RR of 1) (Table V).
3.4.2. Impact of bias adjustment on effect estimates. Using the bias-adjusted effect estimates shifted the pooled
effect estimate towards a lower treatment effect, which was no longer statistically signiﬁcant in any of the
models, although the width of the CI/CrI increased slightly, resulting in larger p-values (Table V). When all
studies were included in the frequentist and Bayesian meta-analyses, adjusting for biases reduced the statistical
heterogeneity from I2= 64% to 42%, from τ2 = 0.36 to 0.28, and from τ2 = 0.80 to 0.69 for the REM (Figure 4),
BREM and BHM models, respectively.
3.4.3. Effect modiﬁcation and sensitivity analyses. Univariate meta-regression showed no statistically signiﬁ-
cant effect modiﬁcation for any variables with either the reported or with the bias-adjusted RRs in REM anal-
ysis (Appendix Table A6, Figure 5). REM bivariate meta-regression models identiﬁed no statistically
signiﬁcant pair of covariates explaining between-study heterogeneity (Appendix Table A7). This ﬁnding was
similar for the Bayesian models (Appendix Table A8). Sensitivity analyses substituting non-informative priors
for the variance with weakly informative priors in BHM of all studies showed robustness of analyses and re-
sulted in narrower credibility intervals (Appendix Table A9).
Figure 3. Classical random effects meta-analysis of observed and bias-adjusted effect estimates
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4. DISCUSSION
Evaluating the comparative effectiveness of MD technologies often involves evidence from multiple
study designs (e.g. RCTs and OSs); raising the question of whether this evidence can be combined into
a single meta-analysis (Higgins and Green, 2011). For HTAs, a single combined effect estimate may not
only be needed to provide an overall assessment of the relative clinical effectiveness of an MD, but also
required to conduct cost-effectiveness analyses. Using THR as an illustrative case, we compared the risk
of revision of cemented and uncemented implant ﬁxation modalities by pooling alternative sources of
data.
Figure 4. Stepwise meta-analysis for the frequentist random effects model
Figure 5. Subgroups in classical random effects meta-analyses bias-unadjusted and bias-adjusted
EVIDENCE SYNTHESIS OF RCT AND OBSERVATIONAL DATA 57
© 2017 The Authors. Health Economics published by John Wiley & Sons, Ltd. Health Econ. 26(Suppl. 1): 46–69 (2017)
DOI: 10.1002/hec
Comparing several frequentist and Bayesian evidence synthesis approaches, we showed that the effect
estimates for revision rates were very similar between the frequentist and Bayesian random effects models,
with wider 95%CrI than the 95%CI, likely because of the wide-ranging uniform priors. Overall, the
pooled results strongly depended on the inclusion of OSs as well as using bias-adjusted estimates. To un-
derstand the potential bias introduced by including unadjusted observational data, the point estimates and
relative CI or CrI widths between the different analyses should be compared simultaneously. We showed
that in the frequentist analyses, statistical signiﬁcance was achieved only when both shifts in point esti-
mate and a narrowing of the uncertainty bounds occurred simultaneously, which may be a common occur-
rence for meta-analyses of MD studies. In our study, including bias-adjusted data from OSs may not have
inﬂuenced a decision based exclusively on statistically signiﬁcant treatment effects compared to restricting
evidence from RCTs only. As bias adjustments using expert elicitation increased the uncertainty because
of OS bias, this counterbalanced the gain in statistical power of adding large registry studies. However, if
the objective is to identify the best point estimate of treatment effect to inform cost-effectiveness
modelling, then a shift in effect size may inﬂuence the ultimate results yielded from calculating cost-
effectiveness ratios.
Expert bias elicitation is a potentially attractive approach, because bias assessment is a common step in each
systematic review of clinical effectiveness. HTA assessors are familiar with concepts of bias assessment such as
applied in the Cochrane risk of bias tools (Sterne et al. 2014). However, for the purposes of adjusting for biases
in statistical modelling analysts need to go beyond qualitative grading (i.e. low or high risk) and quantify the
numerical magnitude of the biases. We demonstrated the use of a modiﬁed method of bias modelling in evi-
dence synthesis using both Bayesian and standard frequentist meta-analysis. This exercise illustrates how OS
data can be included in a meta-analysis, thereby incorporating a larger spectrum of clinically relevant healthcare
data.. However, to ensure internal validity, the data from OSs should be sufﬁciently controlled for confounding
or selection bias through the study design and/or primary analysis, or—if this is not possible—bias adjustment
post-hoc should be applied to the results to minimize internal biases. As external validity always depends on the
context of the decision maker and setting, bias adjustments for external validity should always be considered
separately.
As the method of bias-adjustment elicitation inherently relies on judgment, expert opinion may be consid-
ered unreliable and overly subjective. To maximize the reliability of the expert opinion, we elicited biases from
a group of clinical and methodological experts using a formal approach. Although some judgments on biases
differed between the assessors, these differences were generally small, particularly related to the width of the
95% CIs around the RR of revision, which may potentially reﬂect the different levels of uncertainty among as-
sessors about the effect of the biases.
We modiﬁed a method of bias modelling in evidence synthesis developed by Turner and colleagues that
allows the meta-analysis of RCT and OS to be adjusted for potential biases formally elicited from experts
(Turner et al., 2009). In particular, we implemented some important adaptations to the original elicitation
methodology described by Turner et al. (2009). We requested each assessor to provide a single bias-
adjusted estimate, accounting for the internal (or external) biases of that study. We believe that this adap-
tation has a number of advantages. First, we were able to reduce the burden on the assessors. For example,
providing a bias-adjusted treatment effect estimate for each study for each element of bias, each assessor
would have been required to perform approximately 30 elicitations (i.e. 5 studies × 6 dimensions of bias).
Second, disentangling the impact of each speciﬁc bias on the treatment effect is difﬁcult. We gathered feed-
back from the methodologists and found that quantifying the impact of each single bias on the treatment
effect would have been even more difﬁcult. In the original method (Turner et al. 2009), an assumption
of independence between each speciﬁc bias was made; however, this assumption was not veriﬁed and
may not be the case in practice. Third, although our approach remains cognitively demanding and challeng-
ing for methodological and clinical assessors, we believe that it was more intuitive for them to quantify the
importance of bias in terms of the impact of treatment effects, rather than trying to quantify the bias per se.
Fourth, eliciting an aggregate bias weight per study is in line with the way in which expert judgement is
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currently used in the context of HTA processes, such as those from the NICE in England and Wales. As
part of NICE’s deliberative processes, experts are occasionally invited to provide judgement on the direction
and potential magnitude of biases associated with published estimates of treatment effects. We acknowledge
that this more simpliﬁed bias-adjustment approach may be less precise than if all weights were elicited sep-
arately. However, we believe a simplifying approach was necessary because of the signiﬁcant investment
required to provide training and to support the learning process of experts to individually elicit different
types of bias.
Although our experts agreed that identifying bias weights was conceptually or qualitatively feasible, quan-
tifying the magnitude was quite challenging. Future evidence synthesis studies aiming to bias adjust estimates
of treatment effects should: (i) be appropriately resourced to enable individual elicitation of bias adjusting
weights for each study and bias type, and (ii) acknowledge the need to fund and develop appropriate training
tools to support clinical expert’s in the process of drawing forth quantitative expressions (i.e. eliciting
judgment) of unobservable quantities.
The key strength of this study was that we sought to apply a previously deﬁned bias elicitation
framework to the meta-analysis of randomized experimental and observational evidence. The study also
has a number of limitations. First, we purposively sampled our assessors and the sample size was small.
We therefore need to be cautious about the generalizability of both bias-adjusted meta-analyses and the
experiences of performing this elicitation exercise. Second, while we used an existing framework for
study bias, we may not have fully captured all the relevant biases. We observed heterogeneity among
studies following bias adjustments that remained approximately 40% in REM meta-analysis. In other
words, the variance parameter τ2, representing unexplained between-study heterogeneity, was non-zero,
suggesting that there could be other biases that remain unaddressed. Third, many of the THR studies
included in this exercise were relatively old, prior to the publication of CONSORT (Schulz et al.,
2010) and STROBE (von Elm et al., 2007) frameworks for the reporting of RCT and OS, respectively.
Therefore, in many cases, there was often insufﬁcient detail of study methodology reported to fully
assess the nature and level of bias. Furthermore, time-to-event data would have been the preferred out-
come measure, but were only available in a limited number of published studies. Integration of individ-
ual patient data from registries may have allowed for ﬁtting empirical survival curves but was outside
the scope of the current analysis. Importantly, our study is not meant to inform the clinical
effectiveness of cemented vs. uncemented ﬁxation modalities; rather, our study was meant to be a meth-
odological exercise.
This bias-adjustment methodology has potentially wide application that includes all situations where
there may be caution to pool studies because of high heterogeneity, differences in study design or method-
ological quality. Another use would be for situations where a single point estimate is needed (e.g. as input
in a cost-effectiveness model for an HTA). An alternative and less subjective approach to bias adjustment
could involve using published estimates of the magnitude of bias derived from meta-epidemiological re-
search comparing the inﬂuence of different design elements within RCTs on intervention effects (Savovic
et al., 2012) as well as between study designs (Sacks et al., 1982; Ioannidis et al., 2001; MacLehose
et al., 2000; Deeks et al., 2003). However, RCTs currently have only published quantitative estimates of
the bias impact for a small number of internal bias attributes e.g. detection bias in terms of outcome
blinding, non-random group assignment after imperfect concealment of allocation sequence—and therefore
breaking the randomization leading possibly to confounding-by-indication. There is, to our knowledge, no
data that quantify the extent and direction of bias in OSs compared to RCTs in the ﬁeld of MD
meta-epidemiological research. In fact, conducting meta-epidemiological research improves the inherent
limitations of expert elicitation as the bias is not directly observable. It is also likely that elicited expert
opinion from methodologists was inﬂuenced by their knowledge of meta-epidemiological research, because
the direction of adjustment on average assumed overestimation of treatment effect in most cases. Further-
more, it is preferable to collect information on known and likely confounders within the registry to directly
adjust effect estimates for confounding baseline covariates and time-dependent confounding by adequate
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methods (Cox et al. 2009; Johnson et al., 2009), so that as less as possible is left to subjective bias adjust-
ment by expert elicitation.
5. CONCLUSION
Combining sources of evidence from RCTs, OSs and large national registries into a single pooled effect
estimate may improve the assessment of clinical effectiveness of MDs and the associated decision uncer-
tainty for policy makers. Our case study provides evidence of the feasibility of using data from OSs to
complement RCTs and formalizes the use of expert judgement to bias-adjusted outcomes within the con-
text of standard meta-analysis. We recommend considering the use of expert elicited bias-adjustment
methods in a sensitivity analysis, when combining evidence from RCT and OSs. Additional MD case
studies are needed to demonstrate the acceptability of this approach in the HTA community across other
disease areas.
APPENDIX
Table A1. Classiﬁcation of hip prostheses
Prostheses are usually classiﬁed according to:
1. Fixation How the prostheses are attached to host bone. Both components can be cemented into place with
polymethylmethacrylate (called cemented), both components can be attached to host bone without cement
(known as uncemented) or the femoral stem can be cemented and the acetabulum cementless (called hybrid
hip replacements).
2. Bearing surface or
articulation
This refers to the composition of the femoral head and the inside of the acetabulum, which are the two parts
that move against each other. The femoral head can be ceramic or metal and the acetabular bearing can be
metal, ceramic or polyethylene.
3. Femoral head size Commonly between 22.225 mm and 36 mm
Table A2. Listing of domains of internal bias
Internal bias Description
Selection bias Refers to when some eligible participants, or the initial follow-up time of some participants are excluded in a way that
leads to the association between intervention and outcome differing from the association that would have been
observed in complete follow-up of the ideal trial. It relates, for instance, to generation of a randomised sequence or
concealment of allocations prior to assignment.
Performance bias Performance bias is because of knowledge of the allocated interventions by participants and personnel during the
study. It relates to blinding of study participants and personnel from knowledge of which intervention a participant
received.
Detection bias Detection bias is because of knowledge of the allocated interventions by outcome assessors.
Attrition bias Attrition bias is because of amount, nature or handling of incomplete outcome data. It relates to completeness of
outcome data for each main outcome, including attrition and exclusions from the analysis.
Confounding A confounder is an independent risk factor of the outcome of interest that is associated with the exposure/intervention
in the study population and is not an intermediate step in the causal pathway between the exposure/intervention and
the outcome.
Other bias This dimension covers any important concerns about bias not addressed in the other domains, for instance the sponsor
for the study.
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Table A3. Listing of external biases
External bias Description
Population-related Are the eligibility criteria a proper reﬂection of the study population? Can study results be generalized beyond the
eligibility criteria? (Selection of study population, age, comorbidities, exclusion of patients at risk of complications,
proportion of patients who declined randomization)
Intervention-related Are there differences between the study protocol and routine practice? (Study intervention, timing of treatment,
prohibition of certain non-trial treatments, therapeutic or diagnostic advances since trial was performed)
Comparator-related Are there differences between the study protocol and routine practice? (Appropriateness/relevance of control
intervention)
Outcomes-related Who measured the outcome? Adequacy of the length of follow-up?
Setting-related Do differences in treatment setting translate into possible differences in treatment effects? Do temporal and
geographical differences between study population and target populations translate into a limited generalizability?
(Health care system, country, participating centres, treatment setting, treating physicians)
Table A4. Qualitative bias-assessment—most likely (i.e. mode) impact of dimensions of internal bias for each study
Study Study type Selection Performance Detection Attrition Confounding Other
Wykman (1991) RCT ? ? ? 0/+ ? ?
Reigstad(1993) RCT ? ? ? + ? ?
McCombe (2004) RCT 0 ? ? 0 ? ?
Bjorgul (2010) RCT  ? ?/0 0 ? ?
Corten (2011) RCT 0 0 0 ? ? 0
Kim (2011) RCT 0 ? ? 0 ? ?
Angadi (2012) RCT  ? ? ? ? ?/0
Hailer (2010) Registry ? ? ? ?/0 ?/0 ?
Makela (2010) Registry 0 ? ? ?/0 ?/0 0
Pennington(2013) Registry  ? ? ? 0 ?
Clohisy (2001) Cohort 0 ? 0 0 ? 0
Kim (2003) Cohort +/ ? ? ? ? ?
Kruchans (2004) Cohort NA ? ? ? ? ?
Pospula (2008) Cohort  ? ? 0 ?/ ?
Hartoﬁlakidis (2009) Cohort  ? ? 0 ?/ 0
0, not causing any bias/not likely to favor either implant; +, likely to favor cemented implant; , likely to favor uncemented implant; ?, Do
not know; RCT, randomized clinical trial; NA, not applicable (each assessor gave a different answer).
Table A5. Qualitative bias-assessment—most likely (i.e. mode) impact of dimensions of external bias for each study
Study Study type Population Intervention Comparator Outcome Setting
Wykman (1991) RCT 0   0/+ 0
Reigstad(1993) RCT 0 0 0/+ 0 0
McCombe (2004) RCT 0 0 0 0/+ 0
Bjorgul (2010) RCT  0 0 0 0
Corten (2011) RCT  0 0 0 0
Kim (2011) RCT 0 0 0 0 0
Angadi (2012) RCT 0/ 0 0 1/ 0
Hailer (2010) Registry 0 0 0 + +
Makela (2010) Registry 0 0 + 0 0/
Pennington (2013) Registry 0/ 0 + + 0
Clohisy (2001) Cohort 0 0/   
Kim (2003) Cohort 0   0 0
Kruckhans (2004) Cohort + + + NA 0
Pospula (2008) Cohort ? 0  0 0
Hartoﬁlakidis (2009) Cohort  0 0 0 
0, not causing any bias/not likely to favor either implant; +, likely to favor cemented implant; , likely to favor uncemented implant; ?, Do
not know; RCT: randomized clinical trial; NA, not applicable (each assessor gave a different answer).
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Table A6. Results from ﬁve univariate meta-regressions using frequentist random effects models and Bayesian random
effects models
Frequentist REM
Unadjusted Bias-adjusted
RR (95%CI) p-value RR (95%CI) p-value
Explained Tau2 Explained Tau2
Female proportion 1.36 (0.24–7.81) 0.709 1.60 (0.34–7.51) 0.526
Tau2 = 0.11 Tau2 = 0.06
Age mean 0.995 (0.97–1.03) 0.729 1.00 (0.98–1.03) 0.826
Tau2 = 0.10 Tau2 = 0.06
Study type
RCTs (reference) 1.00 1.00
Registries 0.67 (0.40–1.13) 0.122 0.70 (0.46–1.06) 0.087
Cohorts 0.65 (0.32–1.30) 0.201 0.69 (0.38–1.25) 0.201
Tau2 = 0.05 Tau2 = 0.02
Follow-up (per year) 1.02 (0.96–1.08) 0.541 0.999(0.94–1.06) 0.970
Tau2 = 0.10 Tau2 = 0.06
Unadjusted RR 0.83(0.43 – 1.58) 0.536 0.87 (0.47–1.58) 0.610
Tau2 = 0.10 Tau2 = 0.06
Bayesian REM
Unadjusted Bias-adjusted
RR (95%CI) DIC RR (95%CI) DIC
Explained Tau2 Explained Tau2
Female proportion 1.02 (0.16–7.61) 40.53 1.31 (0.55–4.66) 17.55
Tau2 = 0.69 Tau2 = 0.15
Age mean 0.98 (0.93–1.03) 40.75 1.00 (0.98–1.02) 19.27
Tau2 = 0.66 Tau2 = 0.16
Study type
RCTs (reference) 1.03 (0.53–2.09) 41.05 1.02 (0.71–1.50) 18.80
Registries 1.09 (0.62–2.19) 0.97 (0.68–1.34)
Cohorts Tau2 = 0.70 Tau2 = 0.16
Follow-up (per year) 1.03 (0.92–1.15) 0.70 41.44 1.01 (0.96–1.07) 18.94
Tau2 = 0.70 Tau2 = 0.16
CI, conﬁdence interval; CrI, credibility interval; Tau2, between study variance; DIC, Deviance Information Criterion.
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Table A7. Results from different bivariate meta-regression models of frequentist random effects models
Variable Unadjusted RR (95%CI) p-value Bias-adjusted RR (95%CI) p-value
Female proportion 1.51 (0.22–10.34) 0.647 1.59 (0.31–8.29) 0.551
Mean age (per year) 0.99 (0.96–1.03) 0.660 1.00 (0.97–1.03) 0.911
Constants 0.94 (0.13–7.05) 0.949 0.60 (0.09–3.97) 0.569
Explained Tau2: 0.13 0.07
Female proportion 2.12 (0.79 – 5.71) 0.122 2.39 (0.89–6.44) 0.07
Study type
RCTs 1.00 (reference) 1.00 (reference)
Registries 0.55 (0.37–0.83) 0.008 0.59 (0.43–0.81) 0.003
Cohorts 0.55 (0.28–1.07) 0.074 0.58 (0.34–0.98) 0.044
Constants 0.79 (0.44–1.40) 0.380 0.80 (0.47–1.38) 0.388
Explained Tau2: 0.004 0.0
Female proportion 1.44 (0.22–9.26) 0.680 1.62 (0.32–8.24) 0.531
Follow-up (per year) 1.02 (0.95–1.09) 0.538 0.999(0.94–1.06) 0.965
Constants 0.53 (0.15–1.88) 0.298 0.66 (0.23–1.93) 0.420
Explained Tau2: 0.13 0.07
Mean age (per year) 0.99 (0.96–1.03) 0.586 1.00 (0.97–1.03) 0.875
Study type
RCTs 1.00 (reference) 0.234 1.00 (reference)
Registries 0.71 (0.39–1.29) 0.206 0.72 (0.45–1.15) 0.150
Cohorts 0.61 (0.27–1.37) 0.73 (0.36–1.46) 0.334
Constants 1.74 (0.19–16.05) 0.593 0.94 (0.14–6.31) 0.940
Explained Tau2: 0.07 0.04
Mean age (per year) 1.00 (0.96–1.04) 0.963 1.00 (0.97–1.04) 0.811
Follow-up (per year) 1.02 (0.94–1.10) 0.629 1.00 (0.94–1.07) 0.927
Constants 0.69 (0.05–10.06) 0.769 0.66 (0.06–7.69) 0.717
Explained Tau2: 0.12 0.07
Study type
RCTs 1.00 (reference) 1.00 (reference)
Registries 0.70 (0.39–1.25) 0.202 0.73 (0.45–1.16) 0.162
Cohorts 0.68 (0.321–1.45) 0.289 0.71 (0.37–1.35) 0.262
Follow-up (per year) 1.01 (0.95–1.08) 0.674 0.99 (0.94–1.05) 0.831
Constants 0.88 (0.41–1.91) 0.727 1.12 (0.59–2.12) 0.695
Explained Tau2: 0.07 0.04
95%CI, 95% conﬁdence interval; Tau2, between study variance.
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Table A8. Results from different bivariate meta-regression models of Bayesian random effects model
Variable Unadjusted RR (95%CrI) DIC Bias-adjusted RR (95%CrI) DIC
Female proportion 1.04 (0.47–2.76) 40.81 1.10 (0.65–2.66) 19.28
Mean age (per year) 0.98 (0.93–1.02) 1.00 (0.97–1.02)
Constants 2.89 (0.15–61.0) 0.75 (0.18–3.42)
Explained Tau2: 0.67 0.02
Female proportion 1.00 (0.40–2.56) 41.15 1.08 (0.66–2.15) 18.87
Study type
RCTs 1.00 (reference) 1.00 (reference)
Registries 1.03 (0.55–2.03) 1.02 (0.71–1.47)
Cohorts 1.08 (0.63–2.12) 0.97 (0.69–1.33)
Constants 0.66 (0.31–1.31) 0.71 (0.46–1.03)
Explained Tau2: 0.70 0.15
Female proportion 1.02 (0.42–2.65) 41.53 1.12 (0.66–2.80) 18.97
Follow-up (per year) 1.03 (0.93–1.15) 1.01 (0.96–1.07)
Constants 0.52 (0.15–1.72) 0.62 (0.30–1.17)
Explained Tau2: 0.70 0.15
Mean age (per year) 0.98 (0.93–1.03) 41.25 1.00 (0.97–1.02) 20.21
Study type
RCTs 1.00 (reference) 1.00 (reference)
Registries 1.03 (0.67–1.71) 1.02 (0.76–1.40)
Cohorts 0.99 (0.62–1.57) 0.97 (0.69–1.29)
Constants 2.95 (0.13–70.0) 0.83 (0.16–4.26)
Explained Tau2: 0.67 0.16
Mean age (per year) 0.98 (0.92–1.03) 42.54 1.00 (0.97–1.03) 21.26
Follow-up (per year) 1.01 (0.90–1.13) 1.01 (0.95–1.07)
Constants 2.59 (0.06–134) 0.65 (0.09–5.03)
Explained Tau2: 0.71 0.17
Study type 41.96 20.16
RCTs 1.00 (reference) 1.00 (reference)
Registries 1.01 (0.63–1.65) 1.01 (0.75–1.38)
Cohorts 1.06 (0.70–1.79) 0.98 (0.73–1.29)
Follow-up (per year) 1.03 (0.93–1.15) 1.01 (0.96–1.07)
Constants 0.51 (0.17–1.52) 0.67 (0.39–1.17)
Explained Tau2: 0.71 0.16
CrI, credibility interval; Tau2, between study variance; DIC, Deviance Information Criterion; RCT, randomized controlled trial; RR, relative
risk.
Table A9. Sensitivity analyses for prior distributions in the Bayesian random effects model
Prior distribution of
variance
RR (95%CrI) RR (95%CrI) RR (95%CrI)
RCTs RCTs and registries All studies
Uniform (base case) 0.90 (0.37–1.71) 0.80 (0.55–1.17) 0.77 (0.58–1.03)
Gamma 1.11 (0.84–1.40) 0.80 (0.59–1.11) 0.77 (0.60–1.00)
Inverse Gamma 0.99 (0.53–1.51) 0.80 (0.58–1.11) 0.77 (0.60–1.00)
Half-Cauchy — — 0.67 (0.28–2.21)
RCT, randomized controlled trial; 95%CrI, 95%credibility interval; Tau2, between study variance.
P. SCHNELL-INDERST ET AL.64
© 2017 The Authors. Health Economics published by John Wiley & Sons, Ltd. Health Econ. 26(Suppl. 1): 46–69 (2017)
DOI: 10.1002/hec
Figure A1. An example of a qualitative assessment tool
Figure A2. An example of a quantitative assessment too
EVIDENCE SYNTHESIS OF RCT AND OBSERVATIONAL DATA 65
© 2017 The Authors. Health Economics published by John Wiley & Sons, Ltd. Health Econ. 26(Suppl. 1): 46–69 (2017)
DOI: 10.1002/hec
CONFLICTS OF INTEREST
The research leading to these results has received funding from the European Community’s Seventh Framework
Programme under grant agreement HEALTH-F3-2012-305694 (Project MedtecHTA ‘Methods for Health Tech-
nology Assessment of Medical Devices: a European Perspective’). All authors declare no conﬂict of interest.
ETHICAL STATEMENT
This study did not involve patients.
ACKNOWLEDGEMENTS
The research leading to these results has received funding from the European Community’s Seventh Framework
Programme under grant agreement HEALTH-F3-2012-305694 (Project MedtecHTA ‘Methods for Health Tech-
nology Assessment of Medical Devices: a European Perspective’). We are extremely grateful to the clinical and
methodological experts who took the time from their busy schedules to participate in the study. Without their
support, we would have never achieved the results presented in this manuscript. All errors are ours.
REFERENCES
Angadi DS, Brown S, Crawfurd EJ. 2012. Cemented polyethylene and cementless porous-coated acetabular components
have similar outcomes at a mean of seven years after total hip replacement: a prospective randomised study. Journal
of Bone and Joint Surgery (British) 94: 1604–10.
Figure A3. Elicitation of bias-adjusted treatment effects
P. SCHNELL-INDERST ET AL.66
© 2017 The Authors. Health Economics published by John Wiley & Sons, Ltd. Health Econ. 26(Suppl. 1): 46–69 (2017)
DOI: 10.1002/hec
Bernard A, Vaneau M, Fournel I, Galmiche H, Nony P, Dubernard JM. 2014. Methodological choices for the clinical de-
velopment of medical devices. Medical Devices (Auckl) 7: 325–34.
Bjorgul K, Novicoff WM, Andersen ST, Brevig K, Thu F, Wiig M, Ahlund O. 2010. No differences in outcomes between
cemented and uncemented acetabular components after 12–14 years: results from a randomized controlled trial compar-
ing Duraloc with Charnley cups. Journal of Orthopaedics and Traumatology 11: 37–45.
Clarke A, Pulikottil-Jacob R, Grove A, Freeman K, Mistry H, Tsertsvadze A, Connock M, Court R, Kandala N-B, Costa M,
Suri G, Metcalfe D, Crowther M, Morrow S, Johnson S, Sutcliffe P. 2013. Total hip replacement and surface replace-
ment for the treatment of pain and disability resulting from end stage arthritis of the hip (Review of technology appraisal
guidance 2 and 44). Warwick Evidence 19: 1–668.
Clement ND, Biant LC, Breusch SJ. 2012. Total hip arthroplasty: to cement or not to cement the acetabular socket? A crit-
ical review of the literature. Archives of Orthopaedic and Trauma Surgery 132: 411–27.
Clohisy JC, Harris WH. 2001. Matched-pair analysis of cemented and cementless acetabular reconstruction in primary total
hip arthroplasty. Journal of Arthroplasty 16: 697–705.
Corten K, Bourne RB, Charron KD, Au K, Rorabeck CH. 2011. Comparison of total hip arthroplasty performed with and
without cement: a randomized trial. A concise follow-up, at twenty years, of previous reports. Journal of Bone and Joint
Surgery (American) 93: 1335–8.
Cox E, Martin B, Van Staa T, Garbe E, Siebert U, Johnson ML. 2009. Good research practices for comparative effec-
tiveness research: approaches to mitigate bias and confounding in the design of nonrandomized studies of treatment
effects using secondary data sources: The International Society for Pharmacoeconomics and Outcomes Research
Good Research Practices for Retrospective Database Analysis Task Force Report-Part II. Value in Health 12:
1053–1061.
Deeks JJ, Dinnes J, D’Amico R, Sowden AJ, Sakarovitch C, Song F, Petticrew M, Altman DG, International Stroke Trial
Collaborative Group, European Carotid Surgery Trial Collaborative Group. 2003. Evaluating non-randomised interven-
tion studies. Health Technology Assessment 7: 1–173.
Dekkers OM, Von Elm E, Algra A, Romijn JA, Vandenbroucke JP. 2010. How to assess the external validity of therapeutic
trials: A conceptual approach. International Journal of Epidemiology 39: 89–94.
Faulkner A, Kennedy LG, Baxter K, Donovan J, Wilkinson M, Bevan G. 1998. Effectiveness of hip prostheses in pri-
mary total hip replacement: a critical review of evidence and an economic model. Health Technology Assessment
2: 1–133.
Fitzpatrick R, Shortall E, Sculpher M, Murray D, Morris R, Lodge M, Dawson J, Carr A, Britton A, Briggs A. 1998. Pri-
mary total hip replacement surgery: a systematic review of outcomes and modelling of cost-effectiveness associated with
different prostheses. Health Technology Assessment 2: 1–64.
Froud R, Underwood M, Carnes D, Eldridge S. 2012. Clinicians’ perceptions of reporting methods for back pain trials: A
qualitative study. The British journal of general practice: the journal of the Royal College of General Practitioners
62: e151–9.
Gelman A. 2006. Prior distributions for variance parameters in hierarchical models. Bayesian Analysis 1: 515–533.
Hailer NP, Garellick G, Karrholm J. 2010. Uncemented and cemented primary total hip arthroplasty in the Swedish Hip
Arthroplasty Register. Acta Orthopaedica 81: 34–41.
Hartoﬁlakidis G, Georgiades G, Babis GC. 2009. A comparison of the outcome of cemented all-polyethylene and
cementless metal-backed acetabular sockets in primary total hip arthroplasty. Journal of Arthroplasty 24: 217–25.
Higgins J, Green S. 2011. Cochrane handbook for systematic reviews of interventions version 5.1.0 [Online]. (Available:
www.cochrane-handbook.org, accessed on 21 January 2015).
Iglesias C. 2015. Does assessing the value for money of therapeutic medical devices require a ﬂexible approach? Expert
Review of Pharmacoeconomics & Outcomes Research 15: 21–32.
Ioannidis JPA, Haidich A-B, Pappa M, Kokori SI, Tektonidou MG, Contopoulos-Ioannidis DG, Lau J. 2001. Comparison
of evidence of treatment effects in randomised and nonrandomised studies. Journal of the American Medical Association
286: 821–830.
Johnson ML, Crown W, Martin BC, Dormuth CR, Siebert U. 2009. Good research practices for comparative effectiveness
research: analytic methods to improve causal inference from nonrandomized studies of treatment effects using secondary
data sources: The ISPOR Good Research Practices for Retrospective Database Analysis Task Force Report—Part III.
Value in Health 12: 1062–1073.
Kim YH, Kim JS, Park JW, Joo JH. 2011. Comparison of total hip replacement with and without cement in patients younger
than 50 years of age: the results at 18 years. Journal of Bone and Joint Surgery (British) 93: 449–55.
Kim YH, Oh SH, Kim JS, Lee SH. 2003. Total hip arthroplasty for the treatment of osseous ankylosed hips. Clinical
Orthopaedics and Related Research 414: 136–48.
Konstam MA, Pina I, Lindenfeld J, Packer M. 2003. A device is not a drug. Journal of Cardiac Failure 9: 155–7.
Kruckhans AR, Dustmann HO. 2004. Indications, methods, and results of cemented, hybrid, and cement-free implantation
of THR. Surgical Technology International 12: 253–7.
EVIDENCE SYNTHESIS OF RCT AND OBSERVATIONAL DATA 67
© 2017 The Authors. Health Economics published by John Wiley & Sons, Ltd. Health Econ. 26(Suppl. 1): 46–69 (2017)
DOI: 10.1002/hec
Lunn DJ, Thomas A, Best N, Spiegelhalter DJ. 2000. WinBUGS—a Bayesian modelling framework: concepts, structure,
and extensibility. Statistics and Computing 10: 325–337.
Maclehose RR, Reeves B, Harvey IM, Sheldon TA, Russell IT, Black AM. 2000. A systematic review of comparisons of
effect sizes derived from randomised and non-randomised studies. Health Technology Assessment 4: 1–154.
Makela KT, Eskelinen A, Pulkkinen P, Virolainen P, Paavolainen P, Remes V. 2011. Cemented versus cementless total hip
replacements in patients ﬁfty-ﬁve years of age or older with rheumatoid arthritis. Journal of Bone and Joint Surgery
(American) 93: 178–86.
Mccombe P, Williams SA. 2004. A comparison of polyethylene wear rates between cemented and cementless cups. A pro-
spective, randomised trial. Journal of Bone and Joint Surgery (British) 86: 344–9.
National Institute for Health and Care Excellence (Nice) 2013. Guide to the methods of technology appraisal 2013. National
Institute for Health and Care Excellence (NICE).
Pakvis D, Van Hellemondt G, De Visser E, Jacobs W, Spruit M. 2011. Is there evidence for a superior method of socket
ﬁxation in hip arthroplasty? A systematic review. International Orthopaedics 35: 1109–18.
Panteli D, Nolting A, Eckhardt H, Kulig M, Busse R. 2016. Published and unpublished evidence in coverage decision-
making for pharmaceuticals in Europe: existing approaches and way forward. Health research policy and
systems/BioMed Central 14: 6.
Pennington M, Grieve R, Black N, Van Der Meulen JH. 2013. Functional outcome, revision rates and mortality
after primary total hip replacement—a national comparison of nine prosthesis brands in England. PLoS One
8: e73228.
Pospula W, Abu Noor T, Roshdy T, Al Mukaimi A. 2008. Cemented and cementless total hip replacement. Critical analysis
and comparison of clinical and radiological results of 182 cases operated in Al Razi Hospital, Kuwait. Medical Princi-
ples and Practice 17: 239–43.
Reigstad A, Rokkum M, Bye K, Brandt M. 1993. Femoral remodeling after arthroplasty of the hip. Prospective randomized
5-year comparison of 120 cemented/uncemented cases of arthrosis. Acta Orthopaedica Scandinavica 64: 411–6.
Rothwell PM. 2010. Commentary: External validity of results of randomized trials: disentangling a complex concept. Inter-
national Journal of Epidemiology 39: 94–6.
Royal Netherlands Academy of Arts and Sciences (KNAW). 2014. Evaluation of new technology in health care. In Need of
Guidance for Relevant Evidence, Royal Netherlands Academy of Arts and Sciences: Amsterdam.
Sacks HS, Chalmers TC, Smith H. 1982. Randomized versus historical controls for clinical trials. American Journal of Med-
icine 72: 233–240.
Savovic J, Jones H, Altman D, Harris R, Juni P, Pildal J, als-nielsen B, Balk E, Gluud C, Gluud L, Ioannidis J, Schulz K,
Beynon R, Welton N, Wood L, Moher D, Deeks J, Sterne J. 2012. Inﬂuence of reported study design characteristics on
intervention effect estimates from randomised controlled trials: combined analysis of meta-epidemiological studies.
Health Technology Assessment 16: 1–82.
Schnell-Inderst P, Mayer J, Lauterberg J, Hunger T, Arvandi M, Conrads-Frank A, Nachtnebel A, Wild C, Siebert U. 2015.
Health technology assessment of medical devices: what is different? An overview of three European projects. Z. Evid.
Fortbild. Qual. Gesundh. wesen 109: 309–318.
Schulenburg JM, Mittendorf T, Kulp W, Greiner W. 2009. Health Technology Assessment (HTA) im Bereich der
Medizinprodukte—gleiches Spiel mit gleichen Regeln? Gesundh ökon Qual manag 14: 144–155.
Schulz KF, Altman DG, Moher D. 2010. CONSORT 2010 statement: updated guidelines for reporting parallel group
randomised trials. BMJ 340: c332.
Siebert M, Clauss LC, Carlisle M, Casteels B, De Jong P, Kreuzer M, Sanghera S, Stokoe G, Trueman P, Lang AW. 2002.
Health technology assessment for medical devices in Europe. What must be considered. International Journal of Tech-
nology Assessment in Health Care 18: 733–40.
Sterne, J, Higgins, J, Reeves, B. & Acrobat-Nrsi, O. B. O. T.D. G. F. 2014. A Cochrane Risk Of Bias Assessment Tool: for
Non-Randomized Studies of Interventions (ACROBAT-NRSI). Version 1.0.0 [Online]. [Accessed 16 March 2015].
Tsertsvadze A, Grove A, Freeman K, Court R, Johnson S, Connock M, Clarke A, Sutcliffe P. 2014. Total hip
replacement for the treatment of end stage arthritis of the hip: a systematic review and meta-analysis. PLoS One
9: e99804.
Turner RM, Spiegelhalter DJ, Smith GC, Thompson SG. 2009. Bias modelling in evidence synthesis. Journal of the Royal
Statistical Society. Series A, Statistics in Society 172: 21–47.
Vale L, Wyness L, Mccormack K, Mckenzie L, Brazzelli M, Stearns SC. 2002. A systematic review of the effectiveness and
cost-effectiveness of metal-on-metal hip resurfacing arthroplasty for treatment of hip disease. Health Technology Assess-
ment 6: 1–109.
Verde PE, Ohmann C. 2014. Combining randomized and non-randomized evidence in clinical research: a review of
methods and applications. Research Synthesis Methods 6: 45–62.
Voigt JD, Mosier MC. 2012. Cemented all-polyethylene acetabular implants vs other forms of acetabular ﬁxation: a system-
atic review and meta-analysis of randomized controlled trials. Journal of Arthroplasty 27: 1544–1553. e10.
P. SCHNELL-INDERST ET AL.68
© 2017 The Authors. Health Economics published by John Wiley & Sons, Ltd. Health Econ. 26(Suppl. 1): 46–69 (2017)
DOI: 10.1002/hec
Von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP. 2007. The Strengthening the Reporting of
Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. PLoS Med-
icine 4: e296.
Welton NJ, Ades AE. 2009. Models for potentially biased evidence in meta-analysis using empirically based priors. Journal
of the Royal Statistical Society A 172.
Welton NJ, Sutton AJ, Cooper NJ, Abrams KR. 2012. Evidence Synthesis for Decision Making in Health Care, Wiley:
Chichester.
Wykman A, Olsson E, Axdorph G, Goldie I. 1991. Total hip arthroplasty. A comparison between cemented and press-ﬁt
noncemented ﬁxation. Journal of Arthroplasty 6: 19–29.
EVIDENCE SYNTHESIS OF RCT AND OBSERVATIONAL DATA 69
© 2017 The Authors. Health Economics published by John Wiley & Sons, Ltd. Health Econ. 26(Suppl. 1): 46–69 (2017)
DOI: 10.1002/hec
